Parcopa Related Published Studies
Well-designed clinical trials related to Parcopa (Carbidopa / Levodopa)
Comparison of orally dissolving carbidopa/levodopa (Parcopa) to conventional oral carbidopa/levodopa: A single-dose, double-blind, double-dummy, placebo-controlled, crossover trial. [2010.12.15]
Night-time bioavailability of levodopa/carbidopa/entacapone is higher compared to controlled-release levodopa/carbidopa. [2010.11]
Reducing dosing frequency of carbidopa/levodopa: double-blind crossover study comparing twice-daily bilayer formulation of carbidopa/levodopa (IPX054) versus 4 daily doses of standard carbidopa/levodopa in stable Parkinson disease patients. [2009.07]
Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy. [2005.03]
Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). [2005.03]
Treatment of end-of-dose wearing-off in parkinson's disease: stalevo (levodopa/carbidopa/entacapone) and levodopa/DDCI given in combination with Comtess/Comtan (entacapone) provide equivalent improvements in symptom control superior to that of traditional levodopa/DDCI treatment. [2005]
Concurrent administration of donepezil HCl and levodopa/carbidopa in patients with Parkinson's disease: assessment of pharmacokinetic changes and safety following multiple oral doses. [2004.11]
Entacapone improves the pharmacokinetic and therapeutic response of controlled release levodopa/carbidopa in Parkinson's patients. [2004.02]
Pharmacokinetic-pharmacodynamic interaction between BIA 3-202, a novel COMT inhibitor, and levodopa/carbidopa. [2004.01]
[Pharmacokinetic comparison of Sinemet and Grifoparkin (levodopa/carbidopa 250/25 mg) in Parkinson s disease: a single dose study] [2003.06]
Levodopa-carbidopa with occlusion in older children with amblyopia. [2002.12]
Entacapone improves the availability of L-dopa in plasma by decreasing its peripheral metabolism independent of L-dopa/carbidopa dose. [2002.10]
Quantitative description of loss of clinical benefit following withdrawal of levodopa-carbidopa and bromocriptine in early Parkinson's disease. [2002.09]
Effect of levodopa and carbidopa in human amblyopia. [2002.03]
Influence of layer position on in vitro and in vivo release of levodopa methyl ester and carbidopa from three-layer matrix tablets. [2002.03]
Brasofensine treatment for Parkinson's disease in combination with levodopa/carbidopa. [2002.02]
Time course of loss of clinical benefit following withdrawal of levodopa/carbidopa and bromocriptine in early Parkinson' s disease. [2000.05]
Immediate-release and controlled-release carbidopa/levodopa in PD: a 5-year randomized multicenter study. Carbidopa/Levodopa Study Group. [1999.09.22]
Occlusion and levodopa-carbidopa treatment for childhood amblyopia. [1998.10]
Randomized, placebo-controlled study of tolcapone in patients with fluctuating Parkinson disease treated with levodopa-carbidopa. Tolcapone Fluctuator Study Group III. [1998.08]
Effect of meal timing on the kinetic-dynamic profile of levodopa/carbidopa controlled release [corrected] in parkinsonian patients. [1998.06]
Levodopa-carbidopa and childhood retinal disease. [1998.04]
Effect of tolcapone on plasma levodopa concentrations after coadministration with levodopa/carbidopa to healthy volunteers. [1997.12]
Comparison of immediate-release and controlled release carbidopa/levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. [1997]
Liquid levodopa/carbidopa produces significant improvement in motor function without dyskinesia exacerbation. [1996.12]
Pharmacokinetic comparison of Sinemet and Atamet (generic carbidopa/levodopa): a single-dose study. [1996.07]
Early morning akinesia in Parkinson's disease: effect of standard carbidopa/levodopa and sustained-release carbidopa/levodopa. [1996.04]
L-DOPA/carbidopa for nocturnal movement disorders in uremia. [1996.04]
Effect of levodopa and carbidopa on recovery of visual function in patients with nonarteritic anterior ischemic optic neuropathy of longer than six months' duration. [1996.01]
Acute effects of COMT inhibition on L-DOPA pharmacokinetics in patients treated with carbidopa and selegiline. [1995.08]
Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. [1995.05]
Effect of entacapone, a COMT inhibitor, on the pharmacokinetics and metabolism of levodopa after administration of controlled-release levodopa-carbidopa in volunteers. [1995.02]
The Sydney Multicentre Study of Parkinson's disease: a randomised, prospective five year study comparing low dose bromocriptine with low dose levodopa-carbidopa. [1994.08]
Fluctuations in plasma levodopa and motor responses with liquid and tablet levodopa/carbidopa. [1994.07]
A controlled trial of levodopa plus carbidopa in the treatment of winter seasonal affective disorder: a test of the dopamine hypothesis. [1994.06]
Catechol-O-methyltransferase inhibitor tolcapone prolongs levodopa/carbidopa action in parkinsonian patients. [1993.12]
A double-blind, placebo-controlled study of the treatment of periodic limb movements in sleep using carbidopa/levodopa and propoxyphene. [1993.12]
Longitudinal study of levodopa/carbidopa for childhood amblyopia. [1993.11]
Levodopa/carbidopa for childhood amblyopia. [1993.10]
Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. [1993.10]
Double-blind, placebo-controlled, crossover study of duodenal infusion of levodopa/carbidopa in Parkinson's disease patients with 'on-off' fluctuations. [1993.09]
A placebo-controlled trial of L-dopa/carbidopa in early cocaine abstinence. [1993.08]
Objective evidence for tolerance, against a background of improvement, during maintenance therapy with controlled release levodopa/carbidopa. [1992]
Parkinson's disease monotherapy with controlled-release MK-458 (PHNO): double-blind study and comparison to carbidopa/levodopa. [1991.06]
Standard and controlled-release levodopa/carbidopa in patients with fluctuating Parkinson's disease on a protein redistribution diet. A preliminary report. [1991.04]
Determinants of gait in the elderly parkinsonian on maintenance levodopa/carbidopa therapy. [1990.07]
Decreased efficacy of levodopa with carbidopa in parkinsonian patients after adrenal-to-caudate implants. [1990.05]
The effect of age on the pharmacokinetics of levodopa administered alone and in the presence of carbidopa. [1989.07]
Well-designed clinical trials possibly related to Parcopa (Carbidopa / Levodopa)
Inhibition of catechol-O-methyltransferase modifies acute homocysteine rise during repeated levodopa application in patients with Parkinson's disease. [2011.06]
Effect of controlled-release levodopa on the microstructure of sleep in Parkinson's disease. [2011.04]
Replacing a dopamine agonist by the COMT-inhibitor tolcapone as an adjunct to L-dopa in the treatment of Parkinson's disease: a randomized, multicenter, open-label, parallel-group study. [2010.05]
Single-dose administration of MK-0657, an NR2B-selective NMDA antagonist, does not result in clinically meaningful improvement in motor function in patients with moderate Parkinson's disease. [2009.07]
Children show individual night-to-night variability of periodic limb movements in sleep. [2009.04.01]
Children show individual night-to-night variability of periodic limb movements in sleep. [2009.04]
Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease. [2008.01]
Safety and tolerability of adjunctive tolcapone treatment in patients with early Parkinson's disease. [2007.09]
Mood-elevating effects of d-amphetamine and incentive salience: the effect of acute dopamine precursor depletion. [2007.03]
Does levodopa slow or hasten the rate of progression of Parkinson's disease? [2005.10]
Entacapone increases levodopa exposure and reduces plasma levodopa variability when used with Sinemet CR. [2005.05]
Duodenal levodopa infusion monotherapy vs oral polypharmacy in advanced Parkinson disease. [2005.01.25]
Levodopa and the progression of Parkinson's disease. [2004.12.09]
Mucuna pruriens in Parkinson's disease: a double blind clinical and pharmacological study. [2004.12]
Double-blind, placebo-controlled study of entacapone in levodopa-treated patients with stable Parkinson disease. [2004.10]
Effect of monoamine reuptake inhibitor NS 2330 in advanced Parkinson's disease. [2004.10]
Delayed administration may improve entacapone effects in parkinsonian patients non-responding to the drug. [2004.09]
Pramipexole vs levodopa as initial treatment for Parkinson disease: a 4-year randomized controlled trial. [2004.07]
Circadian variation in neuroendocrine response to L-dopa in patients with restless legs syndrome. [2004.06.15]
Temporal administration of entacapone with slow release L-dopa: pharmacokinetic profile and clinical outcome. [2004.06]
Quality of life in early Parkinson's disease: impact of dyskinesias and motor fluctuations. [2004.01]
Pharmacokinetics of etilevodopa compared to levodopa in patients with Parkinson's disease: an open-label, randomized, crossover study. [2003.11]
Dementia with Lewy bodies. Review of diagnosis and pharmacologic management. [2003.10]
Levodopa improves physical fatigue in Parkinson's disease: a double-blind, placebo-controlled, crossover study. [2003.10]
Adenosine A(2A) receptor antagonist treatment of Parkinson's disease. [2003.08.12]
Optimizing levodopa pharmacokinetics: intestinal infusion versus oral sustained-release tablets. [2003.05]
Randomized trial of pallidotomy versus medical therapy for Parkinson's disease. [2003.05]
Gender and pramipexole effects on levodopa pharmacokinetics and pharmacodynamics. [2002.05.14]
Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. [2002.04.03]
18F-dopa PET evidence that tolcapone acts as a central COMT inhibitor in Parkinson's disease. [2002.03.01]
Oral solution of levodopa ethylester for treatment of response fluctuations in patients with advanced Parkinson's disease. [2002.03]
The SSRI, citalopram, improves bradykinesia in patients with Parkinson's disease treated with L-dopa. [2002.01]
Methylphenidate increases the motor effects of L-Dopa in Parkinson's disease: a pilot study. [2001.07]
Visual acuities after levodopa administration in amblyopia. [2001.03]
Suppressed sympathetic skin response in Parkinson disease. [2000.12]
The long-duration response to L-dopa in the treatment of early PD. [2000.05.23]
The catechol-O-methyltransferase (COMT) inhibitor entacapone enhances the pharmacokinetic and clinical response to Sinemet CR in Parkinson's disease. [2000.05]
Population pharmacokinetics of tolcapone in parkinsonian patients in dose finding studies. [2000.01]
Effect of tolcapone on the haemodynamic effects and tolerability of desipramine. [2000]
The effect of increasing doses of levodopa on children with strabismic amblyopia. [1999.12]
Switching dopamine agonists in advanced Parkinson's disease: is rapid titration preferable to slow? [1999.04.12]
Lack of a pharmacokinetic interaction at steady state between ropinirole and L-dopa in patients with Parkinson's disease. [1999.02]
Population pharmacodynamic modeling of levodopa in patients with Parkinson's disease receiving entacapone. [1998.07]
Endurance performance in humans: the effect of a dopamine precursor or a specific serotonin (5-HT2A/2C) antagonist. [1997.11]
Lamotrigine trial in idiopathic parkinsonism: a double-blind, placebo-controlled, crossover study. [1997.05]
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. [1997.02]
Tolcapone improves motor function and reduces levodopa requirement in patients with Parkinson's disease experiencing motor fluctuations: a multicenter, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuator Study Group I. [1997.01]
Pergolide: treatment of choice in restless legs syndrome (RLS) and nocturnal myoclonus syndrome (NMS). A double-blind randomized crossover trial of pergolide versus L-Dopa. [1997]
Objective measurement of activation of rigidity: diagnostic, pathogenetic and therapeutic implications in parkinsonism. [1996.06]
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. [1996.04]
The effects of co-administration of benzhexol on the peripheral pharmacokinetics of oral levodopa in young volunteers. [1996.04]
International (NL-UK) double-blind study of Sinemet CR and standard Sinemet (25/100) in 170 patients with fluctuating Parkinson's disease. [1996.03]
COMT inhibition by entacapone does not affect growth hormone or prolactin secretion in healthy volunteers. [1996]
|
